Clinical trials: Depression / Major Depressive Disorder
Major Depressive Disorder
Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)
The objective of this study is to allow patients who have participated in the precursor study of BCI-024 in combination with BCI-049 versus placebo or BCI-024 alone (Protocol #CBM-IT-01) to receive 6 weeks of open-label treatment…
- Trial name
- NCT00731653
- Testing
- Combination Product: BCI-024 + BCI-049
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major
A Study of LY2216684 in Healthy Females
This study involves a single dose of 18 milligrams (mg) LY2216684 taken as 1 or 2 tablets by mouth. The study will evaluate effect of LY2216684 on the pharmacokinetics of an oral contraceptive Ortho Cyclen®.
- Trial name
- NCT01373931
- Testing
- LY2216684, Ortho Cyclen
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Lipopolysaccharide (LPS) Challenge in Depression
LPS Challenge in Individuals with Major Depressive Disorder
- Trial name
- NCT03142919
- Testing
- Lipopolysaccharide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Major Depressive Disorder
Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder
To compare the efficacy of escitalopram fixed dose 20 mg/day in combination with fixed doses of gaboxadol (5 and 10 mg/day) versus escitalopram fixed dose 20 mg/day after 8 weeks of treatment in patients with Major Depressive…
- Trial name
- NCT00807248
- Testing
- Escitalopram 20 mg, Gaboxadol 5 mg, Gaboxadol 10 mg
- Where
- 22 sites in Austria, Russia
- Volunteers
- 490 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03739203
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 112 sites in United States, Canada and 6 more
- Volunteers
- 752 people
- Sponsor
- AbbVie
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Major Depressive Disorder
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
- Trial name
- X-NOVA (NCT05376150)
- Testing
- XEN1101 10 mg, XEN1101 20 mg
- Where
- 20 sites in United States
- Volunteers
- 168 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Depressive Disorder, Bipolar Disorder
Nonconvulsive Electrotherapy: a Proof-of-concept Trial
This study involves pilot testing of a modified version of a proven treatment for mental illness. The treatment, electroconvulsive therapy (ECT) is used to treat more than 100,000 Americans yearly.
- Conditions
- Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT01065597
- Testing
- Nonconvulsive electrotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Maryland, College Park
Depressive Disorder, Major
A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
The study involves a single oral dose of 18 mg (2 x 9mg tablets) LY2216684 taken on 2 occasions, once with activated charcoal and once without activated charcoal.
- Trial name
- NCT01389752
- Testing
- LY2216684, Activated Charcoal
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00406640
- Testing
- Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 595 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01179516
- Testing
- Vortioxetine
- Where
- 61 sites in United States
- Volunteers
- 469 people
- Sponsor
- Takeda
Major Depressive Disorder
A Study for Participants With Major Depression
This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.
- Trial name
- NCT00420004
- Testing
- LY2216684, Escitalopram
- Where
- 7 sites in United States, Romania
- Volunteers
- 469 people
- Sponsor
- Eli Lilly and Company
Depression
Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression
This study will determine the effectiveness of motivational interviewing in improving antidepressant medication adherence among Hispanics.
- Trial name
- NCT00356304
- Testing
- Motivational interviewing, Treatment as usual
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Depression, End Stage Renal Disease
A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}
Patients whose kidneys fail generally require dialysis treatments to sustain life. The ability of patients to make major adjustments in their lives for dialysis is hampered by depression that affects almost one-quarter of such…
- Trial name
- ASCEND (NCT02358343)
- Testing
- Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy
- Where
- 3 sites in United States
- Volunteers
- 184 people
- Sponsor
- University of Washington
Schizophrenia, Bipolar Disorder
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
The purpose of this study is to better understand mental illness and will test the hypotheses that, while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after…
- Conditions
- Schizophrenia, Bipolar Disorder, Healthy, Psychosis
- Trial name
- GABAmech (NCT04004416)
- Testing
- Lorazepam and fMRI
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)
A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of peri- and postmenopausal women with major depressive…
- Trial name
- NCT01121484
- Testing
- desvenlafaxine succinate sustained-release
- Where
- 44 sites in United States
- Volunteers
- 439 people
- Sponsor
- Pfizer
Major Depressive Disorder, Insomnia
Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome
This study will examine the effectiveness of a combination of antidepressant medication and sleep-focused psychotherapy to simultaneously treat sleep difficulties and depression.
- Trial name
- NCT00149825
- Testing
- Escitalopram, CBTI, CTRL
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Major Depressive Disorder
Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients
This study is an open-label, randomized, multi-center study conducted in a typical psychiatric outpatient practice in China. This study is intended to collect data on the efficacy and safety of venlafaxine XR (Efexor XR®) versus…
- Trial name
- NCT00474708
- Testing
- Effexor, SSRI
- Where
- 26 sites in China
- Volunteers
- 1,151 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
The purpose of this study is to evaluate the short-term efficacy and safety of Fluoxetine in Japanese adult participants with Major Depressive Disorder (MDD).
- Trial name
- NCT01808612
- Testing
- Fluoxetine
- Where
- 16 sites in Japan
- Volunteers
- 513 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV